Athira Pharma, Inc.
ATHA
$0.239
$0.014.37%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -18.17% | 28.91% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -38.94% | -9.04% | |||
| Operating Income | 38.94% | 9.04% | |||
| Income Before Tax | 47.80% | -7.01% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 47.80% | -7.01% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 47.80% | -7.01% | |||
| EBIT | 38.94% | 9.04% | |||
| EBITDA | 39.32% | 9.12% | |||
| EPS Basic | 48.06% | -6.63% | |||
| Normalized Basic EPS | 39.23% | 8.69% | |||
| EPS Diluted | 48.06% | -6.63% | |||
| Normalized Diluted EPS | 39.23% | 8.69% | |||
| Average Basic Shares Outstanding | 0.48% | 0.36% | |||
| Average Diluted Shares Outstanding | 0.48% | 0.36% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||